Skip to main content
SpringerLink
Log in
Book cover

EGFR Signaling Networks in Cancer Therapy

  • Book
  • © 2008

Overview

Editors:
  1. John D. Haley

    1. OSI Pharmaceuticals, Inc., Farmingdale, U.S.A.

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. William John Gullick

    1. Dept. Biosciences, University of Kent, Canterbury, Kent, United Kingdom

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Probes the molecular pathways and the intersection of signaling networks which are frequently deregulated in human cancers
  • Describes EGF receptor in a tumor tissue specific context
  • Illustrates the many ways in which EGF receptors contribute to abnormal survival and migration signaling in cancer cells and to epithelial-to-mesenchymal transition and metastasis

Part of the book series: Cancer Drug Discovery and Development (CDD&D)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (23 chapters)

  1. Front Matter

    Pages 1-11
    Download chapter PDF

  2. EGFR Signaling Networks

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. EGFR Receptor Family Extracellular Domain Structures and Functions

      • Antony W. Burgess, Thomas P.J Garrett
      Pages 2-13

    3. EGFR family heterodimers in cancer pathogenesis and treatment

      • Howard M. Stern
      Pages 14-29

    4. Structure-function of EGFR kinase domain and its inhibitors

      • Charles Eigenbrot
      Pages 30-44

    5. Internalization and degradation of EGF receptor

      • Alexander Sorkin
      Pages 45-59

    6. Differential dependence of EGFR and ErbB2 on the molecular chaperone Hsp90

      • Wanping Xu, Len Neckers
      Pages 60-68

    7. Activation of STATs 3 and 5 Through the EGFR Signaling Axis

      • Priya Koppikar, Jennifer Rubin Grandis
      Pages 69-83

    8. The intersection of EGFR and the Ras signaling pathway

      • Marie Wislez, Jonathan M. Kurie
      Pages 84-90

    9. PHOSPHOINOSITIDE 3-KINASE ENZYMES AS DOWNSTREAM TARGETS OF THE EGF RECEPTOR

      • Jan Domin
      Pages 91-111

    10. Convergence of EGF Receptor and Src Family Signaling Networks in Cancer

      • Jessica E. Pritchard, Allison B. Jablonski, Sarah J. Parsons
      Pages 112-130

    11. A Molecular Crosstalk between E-cadherin and EGFR Signaling Networks

      • Julie Gavard, J. Silvio Gutkind
      Pages 131-146

    12. Crosstalk Between Insulin-like Growth Factor (IGF) and Epidermal Growth Factor (EGF) Receptors

      • Marc A. Becker, Douglas Yee
      Pages 147-160

    13. Negative regulation of signaling by the EGFR family

      • Kermit L. Carraway III, Lily Yen, Ellen Ingalla, Colleen Sweeney
      Pages 161-178

    14. Nuclear ErbB Receptors: Pathways and Functions

      • Hong-Jun Liao, Graham Carpenter
      Pages 179-189

    15. Temporal Dynamics of EGF Receptor Signaling by Quantitative Proteomics

      • Blagoy Blagoev, Irina Kratchmarova, Jesper V. Olsen, Matthias Mann
      Pages 190-198

    16. Computational and Mathematical Modelling of the EGF Receptor System

      • Colin G. Johnson, Emmet McIntyre, William Gullick
      Pages 199-208

  3. EGFR in Tumorigenesis and EGFR Tyrosine Kinase Inhibitors in Cancer Therapy

    1. Front Matter

      Pages 209-209
      Download chapter PDF

    2. Expression and prognostic significance of the EGFR in solid tumors

      • Nicola Normanno, Caterina Bianco, Antonella De Luca, Luigi Strizzi, Marianna Gallo, Mario Mancino et al.
      Pages 210-223

    3. Signalling by the EGF receptor in human cancers: accentuate the positive, eliminate the negative

      • Haley L. Bennett, Tilman Brummer, Paul Timpson, Kate I. Patterson, Roger J. Daly
      Pages 224-244
Back to top

Keywords

About this book

The epidermal gro wth factor (EGF ) receptor and its downstream signal transduction networks have been implicated in the ontology and maintenance of tumor tissues, which has motivated the discovery and development of molecularly targeted anti-EGF receptor therapies. Over decades of study, the EGF receptor structure, its ligand binding domains, the physical biochemistry underlying its intrinsic tyrosine kinase catalytic function and the modular interactions with SH2, PTB, and SH3 domain containing signaling adaptor p- teins required for signal transduction, have been extensively dissected. Not only is the EGF receptor the nexus of many streams of information, but it also forms one part of a calcul- ing device by forming dimers and oligomers with the other three receptors in its family in response to at least eleven ligands (some of which are expressed in multiple forms with overlapping or quite distinct functions). This phenomenon, while recruiting to the inner surface of the cell membrane and activating multiple second messenger proteins, also allows the possibility of cross talk between these systems, permitting a further layer of information to be exchanged. Less well described are the cross re gulation of the EGF receptor and other anti-apoptotic, mitogenic and metabolic signaling systems. The study of these systems has yielded new surprises. One hurdle in these efforts has been that signal transduction pathways have frequently been defined in the generic absence of their tissue-specific or cell-interaction specific context.

Reviews

From the reviews:

"This book describes the state of EGFR antagonist development and treatment modalities…. This will be of interest to those in academic research studying EGFR signaling and/or cancer. … This is an excellent reference for those focused on a particular aspect of EGFR signaling who are looking for a concise review. This is a timely review of an increasingly complex area of study." (James P. Luyendyk, Doody’s Review Service, January, 2009)

"This book bridges the basic and clinical progress in EGFR network in cancer therapy over 40 years of EGFR research. Due to the contributors’ basic science and clinical backgrounds, the book is … best suited for basic scientists, translational scientists, and oncologists who engage in EGFR associated research and clinical therapy at various levels. The book provides a comprehensive EGFR resource for researchers not only in basic biological fields but also in preclinical and clinical therapy … ." (Guolin Zhang and Eric B. Haura, Cancer Control, Vol. 16 (4), October, 2009)

“This book is a collection of articles from different authors organized into two sections. … a good and useful book for any medicinal chemist working in this field … . all chapters are well written, clear, and rather agreeable to read. … easily understood by even an inexperienced reader. … a useful introduction to the role of EGFR signaling networks in a large number of tumors for novice researchers, but it could also be considered in some way a reference text for more experienced ones.” (Adriano Martinelli, ChemBioChem, Vol. 5, 2010)

Editors and Affiliations

  • OSI Pharmaceuticals, Inc., Farmingdale, U.S.A.

    John D. Haley

  • Dept. Biosciences, University of Kent, Canterbury, Kent, United Kingdom

    William John Gullick

Bibliographic Information

  • Book Title: EGFR Signaling Networks in Cancer Therapy

  • Editors: John D. Haley, William John Gullick

  • Series Title: Cancer Drug Discovery and Development

  • DOI: https://doi.org/10.1007/978-1-59745-356-1

  • Publisher: Humana Totowa, NJ

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Humana Press 2008

  • Hardcover ISBN: 978-1-58829-948-2Published: 25 September 2008

  • Softcover ISBN: 978-1-61737-853-9Published: 20 January 2011

  • eBook ISBN: 978-1-59745-356-1Published: 01 March 2009

  • Series ISSN: 2196-9906

  • Series E-ISSN: 2196-9914

  • Edition Number: 1

  • Number of Pages: XI, 395

  • Topics: Oncology, Cancer Research

Publish with us

Policies and ethics

Back to top

Search

Navigation